Medical Practice, Rheinfelden, Switzerland.
Eur J Intern Med. 2010 Dec;21(6):503-8. doi: 10.1016/j.ejim.2010.09.010. Epub 2010 Nov 5.
Colchicine (COL) has been used in medicine for a long time. It is well recognized as a valid therapy in acute flares of gouty arthritis, familial Mediterranean fever (FMF), Behçet's disease, and recurring pericarditis with effusion. It has also been used to treat many inflammatory disorders prone to fibrosis, mostly with disappointing therapeutic results. The pharmacotherapeutic mechanism of action of COL in diverse diseases is not fully understood, thought it is known that the drug accumulates preferentially in neutrophils, and this effect is useful in FMF. COL shows a large interindividual bioavailability. Furthermore, interactions with drugs interfering with CYP3A4 dependent enzymes and P-glycoprotein occur and are clinically important. The dosage of COL must be reduced in patients with relevant hepatic and/or renal dysfunction. However, when appropriately used and contraindications have been excluded, oral COL is a safe treatment.
秋水仙碱(COL)在医学上的应用由来已久。它已被广泛认可为治疗痛风性关节炎急性发作、家族性地中海热(FMF)、贝切特病和复发性渗出性心包炎的有效疗法。它还被用于治疗许多易发生纤维化的炎症性疾病,但大多疗效不佳。COL 在多种疾病中的药物治疗作用机制尚未完全阐明,但已知该药物优先在中性粒细胞中蓄积,这一作用在 FMF 中是有益的。COL 显示出很大的个体间生物利用度。此外,还会与干扰 CYP3A4 依赖性酶和 P-糖蛋白的药物相互作用,且具有临床意义。在存在相关肝肾功能障碍的患者中,COL 的剂量必须减少。但是,只要正确使用且排除禁忌证,口服 COL 是一种安全的治疗方法。